

Alexa B Schrock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7232018/publications.pdf>

Version: 2024-02-01

106
papers

8,290
citations

94433

37
h-index

51608

86
g-index

106
all docs

106
docs citations

106
times ranked

12129
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Medicine</i> , 2017, 9, 34.	8.2	2,480
2	Acquired Resistance to KRAS ^{G12C} Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	27.0	482
3	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1493-1502.	1.1	288
4	^{Non-V600} <i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2624-2630.	1.6	267
5	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i> -Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206.	1.6	246
6	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	1.3	224
7	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. <i>Oncologist</i> , 2020, 25, e147-e159.	3.7	220
8	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	1.4	192
9	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
10	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	183
11	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. <i>Oncologist</i> , 2017, 22, 1478-1490.	3.7	176
12	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1560-1568.	1.1	158
13	Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 1546.	7.1	154
14	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . <i>Cancer</i> , 2018, 124, 1358-1373.	4.1	151
15	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7.	16.8	145
16	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2017, 12, 932-942.	1.1	129
17	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. <i>Lung Cancer</i> , 2017, 108, 228-231.	2.0	125
18	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 696-713.	9.4	107

#	ARTICLE	IF	CITATIONS
19	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1312-1323.	1.1	103
20	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, 137-140.	1.1	102
21	Identification of <i>NTRK</i> fusions in pediatric mesenchymal tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26433.	1.5	92
22	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 872-877.	1.1	87
23	RET rearrangements are actionable alterations in breast cancer. <i>Nature Communications</i> , 2018, 9, 4821.	12.8	87
24	<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. <i>Oncologist</i> , 2017, 22, 1444-1450.	3.7	81
25	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. <i>Clinical Cancer Research</i> , 2019, 25, 3341-3351.	7.0	80
26	<i>BRAF</i> V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. <i>Cancer Discovery</i> , 2016, 6, 594-600.	9.4	75
27	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 446-457.	1.1	75
28	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	3.7	73
29	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 766-776.	1.1	68
30	Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2019, 14, 54-62.	1.1	64
31	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. <i>Oncologist</i> , 2017, 22, 255-263.	3.7	60
32	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. <i>Clinical Cancer Research</i> , 2018, 24, 1881-1890.	7.0	59
33	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. <i>Cancer</i> , 2017, 123, 3628-3637.	4.1	57
34	Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. <i>Journal of Urology</i> , 2019, 201, 541-548.	0.4	57
35	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 255-264.	1.1	53
36	Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration. <i>Oncologist</i> , 2017, 22, 416-421.	3.7	46

#	ARTICLE	IF	CITATIONS
37	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017, 111, 61-64.	2.0	44
38	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41
39	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 597-602.	2.5	38
40	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e225394.	5.9	37
41	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	3.7	36
42	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. <i>Lung Cancer</i> , 2016, 97, 48-50.	2.0	36
43	Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, e89-e90.	1.1	34
44	Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. <i>Nature Communications</i> , 2021, 12, 1382.	12.8	34
45	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , 2016, 22, 3281-3285.	7.0	33
46	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion–Driven Lung Cancers: The eNRG1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	1.6	32
47	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 831-840.	1.4	31
48	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. <i>European Urology Focus</i> , 2019, 5, 748-755.	3.1	29
49	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	4.4	27
50	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020, 98, 905-912.	1.9	27
51	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	5.0	26
52	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	2.0	25
53	<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	3.0	24
54	Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, e27-e29.	1.1	23

#	ARTICLE	IF	CITATIONS
55	<p>Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 21-26.	2.7	22
56	FRMD4A / RET : A Novel RET Oncogenic Fusion Variant in&Non&€“Small Cell Lung Carcinoma. Journal of Thoracic Oncology, 2017, 12, e15-e16.	1.1	21
57	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. Human Pathology, 2017, 70, 84-91.	2.0	20
58	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clinical Cancer Research, 2022, 28, 728-737.	7.0	20
59	Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion. Clinical Breast Cancer, 2018, 18, e267-e270.	2.4	18
60	EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?. Journal of Thoracic Oncology, 2018, 13, e33-e34.	1.1	17
61	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti&€“PD-1 Therapy. JCO Precision Oncology, 2021, 5, 1821-1829.	3.0	17
62	Identification of a novel T1151K ALK mutation in a patient with ALK -rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer, 2017, 110, 32-34.	2.0	16
63	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist, 2017, 22, 774-779.	3.7	16
64	<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist, 2019, 24, 1462-1468.	3.7	16
65	Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers. Oncologist, 2022, 27, 919-929.	3.7	16
66	Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR -mutated Lung Adenocarcinoma Reveals an Acquired FGFR3 - TACC3 Fusion. Clinical Lung Cancer, 2017, 18, e219-e222.	2.6	15
67	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. BJU International, 2020, 125, 739-746.	2.5	14
68	Clinicopathologic, genomic and protein expression characterization of 356 <scp><i>ROS1</i></scp> fusion driven solid tumors cases. International Journal of Cancer, 2021, 148, 1778-1788.	5.1	14
69	Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an <i>RAF1</i> Fusion. JCO Precision Oncology, 2018, 2, 1-6.	3.0	13
70	The Pan&€“Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	3.7	13
71	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Translational Oncology, 2021, 14, 101184.	3.7	13
72	Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Experimental Hematology and Oncology, 2017, 6, 29.	5.0	12

#	ARTICLE	IF	CITATIONS
73	Characterization of Nonâ€“Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. <i>JCO Precision Oncology</i> , 2021, 5, 1354-1376.	3.0	12
74	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
75	TMPRSS2-ERG Fusions Unexpectedly Identified in Men Initially Diagnosed With Nonprostatic Malignancies. <i>JCO Precision Oncology</i> , 2017, 2017, 1-6.	3.0	10
76	Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 45-47.	2.7	10
77	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	3.0	10
78	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .	3.0	10
79	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e155-e157.	1.1	9
80	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	1.6	9
81	Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Nonâ€“small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e211-e213.	2.6	8
82	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. <i>Oncologist</i> , 2018, 23, 776-781.	3.7	8
83	Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1780-1782.	1.2	7
84	<i>RAS</i> Amplification as a Negative Predictor of Benefit from Anti-EGFRâ€“Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 469-475.	3.7	7
85	The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100194.	1.1	7
86	Real-world association of HER2/<i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. <i>Future Oncology</i> , 2021, 17, 4101-4114.	2.4	7
87	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	1.6	7
88	CD74 - ROS1 Fusion in NSCLCâ€“Detected by Hybrid Captureâ€“Based Tissue Genomic Profiling and ctDNA Assays. <i>Journal of Thoracic Oncology</i> , 2017, 12, e19-e20.	1.1	6
89	A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26377.	1.5	6
90	Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 111-116.	2.7	6

#	ARTICLE	IF	CITATIONS
91	Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report. <i>BMC Cancer</i> , 2017, 17, 197.	2.6	5
92	Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. <i>Oncologist</i> , 2019, 24, 657-663.	3.7	5
93	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	4.1	5
94	Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. <i>Journal of Thoracic Oncology</i> , 2019, 14, e29-e30.	1.1	4
95	Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 440-443.	4.7	4
96	Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	3.0	3
97	Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitor-Associated Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	3
98	ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100330.	3.0	3
99	Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 33-39.	2.7	2
100	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100477.	3.0	2
101	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	3.0	1
102	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	1
103	Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD). <i>Cancer Research</i> , 2022, 82, PD14-09-PD14-09.	0.9	1
104	Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	3.0	0
105	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR- β N848K mutation. <i>Lung Cancer</i> , 2018, 124, 86-89.	2.0	0
106	Abstract P3-07-02: Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): <i>BRCA1/2</i> and beyond. <i>Cancer Research</i> , 2022, 82, P3-07-02-P3-07-02.	0.9	0